Sensitive detection of vascular endothelial growth factor (VEGF 165 ) is important for early cancer disease diagnosis in the clinic. A sensitive fluorescent sensing platform for VEGF 165 detection is developed in this work. It is based on a target-triggered hybridization chain reaction (HCR) and graphene oxide (GO) selective fluorescence quenching. In this assay, in the presence of the VEGF 165 , the hairpin structure of Hp opens up and the initiation sequence will be exposed to Hp1 to open its hairpin structure. Then the opened Hp1 hybridizes with Hp2 to expose the complementary sequence of Hp1 which hybridizes with Hp1 again by HCR. Thus HCR would be initiated, generating super-long dsDNA. After the HCR, the double strands of the HCR product cannot be adsorbed on the GO surface. As a result, the HCR product gives a strong fluorescence signal which is dependent on the concentration of VEGF 165 . By using VEGF 165 as a model analyte, the assay provides a highly sensitive fluorescence detection method for VEGF 165 with a detection limit down to 20 pg mL
Introduction
Cancer has become one of the greatest causes of human death worldwide, 1 and so early diagnosis of cancer is particularly important in reducing cancer mortality. Nowadays, techniques for the clinical diagnosis of cancer depend primarily on the biopsy of diseased cells or tissues and imaging equipment. 2 However, these methods are limited by their low sensitivity in the diagnosis of cancer at an early stage. Biomarkers, including cells, nucleic acids, and proteins, could be used as indicators for the evaluation of either normal or pathological processes. 3, 4 The vascular endothelial growth factor (VEGF 165 ) is a signicant signal protein stimulating vasculogenesis and is secreted by both endothelial and tumor cells. 5 It plays a central role in the regulation of the angiogenesis process. 6 However, VEGF 165 is usually over-expressed in variants of breast and lung cancer and may be a possible predictor of cancers.
7-11 VEGF 165 may be an important biomarker for early cancer disease diagnosis in clinical settings. 12, 13 Thus, the rapid, selective and sensitive detection of VEGF 165 is important for disease diagnosis and subsequent therapy monitoring. To date, various VEGF 165 detection techniques have been reported, including ELISA assays, [14] [15] [16] immunohistochemistry, optical methods, 17 and radioimmunoassay. However, these methods are mainly time-consuming, labor-intensive, and complex and involve expensive reagents. Several novel biosensor methods have also been reported for the detection of VEGF 165 , such as the use of aptamers. Aptamers are short oligonucleotide sequences (ssDNA or RNA), and could be screened in vitro and synthesized with the systematic evolution of ligands. 18 The aptamers have high affinity, specicity, and stability, and simple synthesis, easy labeling and wide applicability compared to traditional molecular recognition systems.
19 Therefore, they are regarded as an alternative to antibody-based methods. Up to now, a variety of aptamer-based analytical strategies for the detection of VEGF 165 have been reported, such as differential pulse voltammetry (DPV), 20, 21 24, 25 and time-resolved uo-rescence (TR-FL). 26 These methods have good specicity and stability compared to traditional approaches. 27, 28 However, they lack a signal amplication strategy, resulting in low sensitivity, a narrow detection range and high error rate. For these reasons, a highly sensitive and selective method with a wide quantitative dynamic range is essential for VEGF 165 detection.
Recently, aptamer-based amplication assays, such as the rolling chain reaction (RCA), 29 polymerase chain reaction assay (PCR), 30 ligase chain reaction (LCR), 31 and nanoparticle-assisted amplication 32 have aroused more attention due to their high sensitivity and wide quantitative dynamic range. However, these methods are highly enzyme-dependent, costly and sensitive to reaction conditions. In addition, the reaction conditions, such as the pH, temperature and buffer media, must be precisely controlled in order to guarantee the activity of the enzymes.
33
As far as we know, the hybridization chain reaction (HCR), one of the most attractive enzyme-free amplication methods, shows great potential in nucleic acid detection. 34, 35 In an HCR system, two DNA hairpin probes Hp1 and Hp2 can coexist stably in solution unless triggered by a primer sequence. 36, 37 When the target was introduced, the hairpin probes changed, initiating a cascade of hybridization events. 38 Therefore, HCR has been regarded as an ideal choice in DNA-based signal amplication for protein detection. 39 Graphene oxide (GO) has gained more and more attention due to its large surface area, good water dispersibility and biocompatibility. 40, 41 Moreover, GO can strongly adsorb single-stranded nucleic acids, but hardly interacts with rigid double-stranded nucleic acids. At the same time, the uorescence signal of the substances adsorbed by GO can be quenched. Therefore, GO can be used as an ideal nanomaterial in uorescent biosensors.
42,43
Herein, we designed a highly sensitive enzyme-free and rapid aptasensing platform for the detection of VEGF 165 based on the HCR. In this assay, in the presence of the VEGF 165 , the hairpin structure of Hp opens up and the initiation sequence will be exposed to Hp1 to open its hairpin structure by a toeholdmediating strand displacement reaction. Once the hairpin of the rst Hp1 opens up, it triggers a cascade reaction, resulting in opening up the hairpin of Hp2, and consequently Hp1, Hp2, Hp1, Hp2 .. Thus the HCR would be initiated, generating superlong dsDNA. The double strands of the HCR product cannot be adsorbed on the GO surface. 44 As a result, the HCR product gives a strong uorescence signal dependent on the concentration of VEGF 165 . More importantly, this simple and rapid amplication strategy can be completed in a short time without expensive enzymes, and provides a novel approach for detection of VEGF 165 . Furthermore, it has been successfully applied to the detection of VEGF 165 in various spiked biological samples, with recovery in the range of 99.7-107.2%. Therefore, one may believe that this sensing system possesses great potential for detection of proteins, biological molecules research and clinical diagnosis.
Experimental section

Reagents and materials
The EpCAM, PSA, BSA and VEGF 165 were purchased from Cusabio Biotech Co. Ltd. All of the reagents were diluted to the required concentration with working buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.4) before use. All of the oligonucleotides used in this work were synthesized and puried using HPLC by Sangon Biotechnology Co. Ltd. (Shanghai, China, https:// www.sangon.com), and their sequences are shown in Table  S1 . † GO was purchased from XFNANO Co. Ltd. (Nanjing, China, https://www.xfnano.com). The other reagents employed were of analytical grade and used without further purication. Healthy human serum, urine and saliva were provided by Affiliated Dongfeng Hospital, Hubei University of Medicine, and approved by the Hospital's Ethics Committee. Ultrapure water obtained from a Millipore water purication system (18.2 MU cm resistivity, Milli-Q Direct 8) was used in all runs.
VEGF 165 sensing procedure
Firstly, a mixture of Hp as well as Hp1 and Hp2 strands were separately heated at 90 C for 5 min, respectively, followed by slow cooling down to room temperature. Next, different concentrations of VEGF 165 were incubated with the Hp solution in working buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.4) for 30 min at 37 C. This was followed by the addition of Hp1 and
Hp2 and incubation at 37 C. Finally, the GO was added and incubated with the reaction solution for 5 min. Then the solution was diluted to 1 mL, and the uorescence intensity of the solution was measured.
Fluorescence measurements
The uorescence detection of the mixtures was carried out on a Hitachi F-4600 spectrophotometer (Hitachi Co. Ltd., Japan, https://www.hitachi.co.jp) equipped with a xenon lamp excitation source at room temperature. The excitation was set at 495 nm and the emission spectra were collected from 510 nm to 600 nm. The slits of the excitation and emission were both set at 5 nm. In control experiments, the measurement process was the same as the above except for the addition of VEGF 165 . Unless otherwise noted, each uorescence measurement was repeated three times, and the standard deviation was plotted as the error bar. To evaluate the effects of potential interfering substances on detection, three different relevant compounds, EpCAM, BSA and PSA at a concentration of 100 ng mL
À1
, were spiked, respectively, and the measurements were performed under the same conditions. A quantitative assay of VEGF 165 was realized by using the uores-cence intensity. F 1 and F 0 are the uorescence intensities at 519 nm in the presence and absence of VEGF 165 , respectively.
Results and discussion
Principle of design
In the present study, the principle of enzyme-free uorescent detection of VEGF 165 based on HCR is illustrated in Fig. 1 . The detection method was composed of three DNA probes, assistant DNA probe (Hp), hairpin probe 1 (Hp1) and hairpin probe 2 (Hp2), and VEGF 165 was adopted as the target protein. Aer the HCR reaction, the GO was added into the solutions, and the free Hp1 and Hp2 were closely adsorbed onto the GO surface via p-p stacking. However, the HCR product cannot be adsorbed on the GO surface, 45,46 realizing a strong uorescence signal.
Feasibility analysis of uorescence VEGF 165 detection
To further verify the feasibility of the HCR/GO uorescence signal amplication strategy, Fig. 2 shows the uorescence emission spectra under different conditions. The uorescence signal produced by a mixed solution of Hp1 and Hp2 (curve a) is relatively strong in the absence of GO. Aer adding the target (curve c) or Hp (curve d), the uorescence intensity was relatively weak in the presence of GO. The reason may be that, when target and Hp were added alone, the HCR reaction could not occur, giving the results that appear in the graph. However, when 10 ng mL À1 of VEGF 165 was added into a mixed solution of Hp1, Hp2
and Hp, a signicant enhancement in the uorescence intensity was observed (curve b) in the presence of GO, indicating that VEGF 165 was specically recognized and triggered the HCR events. These results conrm the feasibility of the proposed uorescence biosensor for VEGF 165 detection by our design.
Optimization of reaction conditions
Whether the uorescence of Hp1 and Hp2 could be effectively quenched by GO is vital for the design of the HCR/GO assay, which is rstly explored in this paper. The uorescence change is related to the concentration of GO shown in Fig. 3A . The maximum F 1 /F 0 value was observed when the concentration of GO was 20 mg mL À1 . When the concentration of GO is increased, however, the F 1 /F 0 value obviously decreases along with the increasing GO concentration. Therefore, 20 mg mL À1 is selected as the optimum GO concentration. At the same time, the reaction time of the HCR is another important factor affecting uorescence intensity. As shown in Fig. 3B , maximum F 1 /F 0 values are observed when the reaction time is 40 min; therefore, 40 min of HCR time was selected for the rest of the experiments. Besides the above conditions, the pH and HCR reaction temperature may also affect the sensitivity. As shown in Fig. S1A , † it can be seen that the uorescence intensity initially increased and then decreased with an increase in pH. The maximum F 1 /F 0 values are observed when the pH is 7.4; therefore, the best pH was pH 7.4. Fig. S1B † shows that the incubation temperature could obviously affect the sensitivity, and the F 1 /F 0 value reached a maximum when the incubation temperature was 37 C and then decreased gradually; thus, an HCR reaction temperature of 37 C was selected in the experimental design.
To obtain high sensitivity, the concentrations of Hp1, Hp2 and Hp were also investigated. As shown in Fig. S2A , † the concentration of Hp1 was selected in the following experiments; the F 1 /F 0 value reached a maximum when the concentration of Hp1 was 30 nM. Therefore, a concentration of 30 nM was selected as the optimal concentration of Hp1, and the concentration of Hp2 is identical to that of Hp1. As shown in Fig. S2B , † the concentration of Hp was selected in the following experiments. The maximum F 1 /F 0 value was observed when the concentration of Hp was 5 nM; thus, 5 nM was conrmed as the optimum reaction concentration of Hp.
Sensitivity and specicity for VEGF 165 detection
In order to make better use of this designed strategy, the sensitivity of the sensor for the detection of VEGF 165 was investigated. As shown in Fig. 4A , in an analysis of different quantities of target, we found that the uorescence intensity was obviously enhanced with an increased quantity of target. Fig. 4B shows that a good linear correlation between the uo-rescence intensity and the logarithm of VEGF 165 concentration ranging from 0.1 ng mL À1 to 500 ng mL À1 was obtained. The regression equation was expressed as y ¼ 155.471 log c À 178.27 (R 2 ¼ 0.9948), where log c is the logarithm of VEGF 165 concentration (pg mL À1 ). According to the 3s rule, the detection limit was calculated to be 20 pg mL À1 . In comparison, such a low detection limit was comparable to or even higher than those reported in the literature and listed in Table 1 .
In addition, the specicity of the sensor was also investigated by adding four kinds of different control proteins, VEGF 165 , PSA, BSA and EpCAM, as shown in Fig. 5 , weak uorescence was exhibited in the presence of PSA, BSA, or EpCAM, compared with the blank control. However, a signicant increase in uorescence signal was observed in the presence of VEGF 165 , indicating that this method exhibited good specicity for VEGF 165 detection. 
Determination of VEGF 165 in real samples
To assess the application of this proposed design in biological samples (all spiked samples were diluted to 10%), human serum, urine and saliva, respectively, were employed as a complex matrix. Before the measurements, the samples were prepared by adding VEGF 165 into blank biological samples including human serum, urine and saliva, respectively. As shown in Fig. 6 , the enhancement in uorescence intensity is observed in various biological samples in the presence of 10 ng mL À1 VEGF 165 , compared with unspiked biological samples.
The results indicate that use of the proposed sensor to analyze VEGF 165 in biological samples was feasible. The recoveries of VEGF 165 spiked to different matrices are listed in Table 2 . The recoveries for the spiked VEGF 165 in human serum, saliva and urine were in the range of 107.2-99.7%, and the RSD (%) were 10.8%, 10.3%, 9.9% at 10 ng mL À1 of VEGF 165 , respectively. This indicates an acceptable precision and reproducibility of the present approach for detecting VEGF 165 in real samples (n ¼ 3).
Conclusions
In conclusion, a novel and enzyme-free highly sensitive assay of uorescent signal amplication was successfully developed for detecting VEGF 165 . In this design, because of the specic recognition of aptamer for VEGF 165 and signal amplication by HCR, selectivity and sensitivity for VEGF 165 were achieved. Besides, the HCR reaction has strong environmental adaptability due to there being no participation of enzymes. Under optimal conditions, the detection limit was as low as 20 pg mL
À1
, and a linearity ranging from 0.1 ng mL À1 to 500 ng mL À1 was obtained. More importantly, this biosensor was successfully applied for the detection of VEGF 165 in various spiked biological samples, and provides a novel approach for the detection of VEGF 165 compared to other reported biosensors. One may believe that it could be a potential method for proteomics and clinical analysis.
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